PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksReneuron Regulatory News (RENE)

  • This share is currently suspended. It was suspended at a price of 3.275

Share Price Information for Reneuron (RENE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.275
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 3.275
RENE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TR-1: Notification of Major Interest in Shares

21 Sep 2012 12:39

RNS Number : 8716M
ReNeuron Group plc
21 September 2012
 



21 September 2012

AIM: RENE

 

ReNeuron Group plc

(the "Company")

 

 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

 

 

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached:

RENEURON GROUP PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

YES

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation:

Toscafund Asset Management LLP

4. Full name of shareholder(s)  (if different from 3.):

Tosca Mid Cap

DB Platinum Tosca Mid Cap Equity Fund

5. Date of the transaction and date onwhich the threshold is crossed orreached:

11/09/2012

6. Date on which issuer notified:

13/09/2012

7. Threshold(s) that is/are crossed orreached:

11%

 

8. Notified details:

A: Voting rights attached to shares

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights

Direct

Direct

Indirect

Direct

Indirect

GB00B0DZML60

85,408,002

85,408,002

83,775,568

0

83,775,568

0

10.82%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate

Exercise/Conversion Period

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date

Exercise/Conversion period

Number of voting rights instrument refers to

 

% of voting rights  

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

83,775,568

10.82%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable:

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Robert Lord

15. Contact telephone number:

020 7845 6100

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLLLFVLARILFIF
Date   Source Headline
28th Mar 20137:02 amRNSCollaboration with Cell Therapy Catapult
27th Mar 20137:00 amRNSDosing Completed in Stroke Trial
26th Mar 20137:00 amRNSApprovals for Stem Cell Trial in CLI
19th Mar 20134:40 pmRNSSecond Price Monitoring Extn
19th Mar 20134:35 pmRNSPrice Monitoring Extension
11th Mar 20137:00 amRNSWins Two Biomedical Catalyst Grants
6th Mar 20134:35 pmRNSPrice Monitoring Extension
25th Feb 20137:00 amRNSAIM Rule 17 Notification
29th Jan 20137:00 amRNSStroke Trial Update: Final Cohort Begins Dosing
11th Jan 20134:40 pmRNSSecond Price Monitoring Extn
11th Jan 20134:35 pmRNSPrice Monitoring Extension
4th Dec 20127:01 amRNSReNeuron to Present at UK Stroke Forum
4th Dec 20127:00 amRNSInterim Results
22nd Nov 20127:00 amRNSNon-Clinical Data
21st Nov 20127:00 amRNSNotification of Interim Results
17th Oct 20127:00 amRNSFurther Progress with Stroke Trial
21st Sep 201212:39 pmRNSTR-1: Notification of Major Interest in Shares
14th Sep 201210:00 amRNSDirectors' Interest in Shares and Share Options
11th Sep 201210:38 amRNSResults of 2012 Annual General Meeting
11th Sep 20127:00 amRNSAGM Trading Update
14th Aug 20127:00 amRNSStroke Trial Update
7th Aug 20129:42 amRNSTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
16th Jul 20127:00 amRNSPosting of Annual Report & Notice of AGM
5th Jul 20124:40 pmRNSSecond Price Monitoring Extn
5th Jul 20124:35 pmRNSPrice Monitoring Extension
28th Jun 20127:01 amRNSSSAG and Non-Executive Board Changes
28th Jun 20127:00 amRNSPreliminary Results
19th Jun 20127:00 amRNSNotification of Preliminary Results
15th Jun 20127:00 amRNSPresents Further Data
14th Jun 20127:00 amRNSPISCES Trial Interim Data
8th Jun 201210:13 amRNSNotice of Major Interest in Shares
21st May 20127:00 amRNSPresentation at World Stem Cells Congress
16th May 20127:00 amRNSCell Manufacturing Contract
11th May 201211:09 amRNSNotifications of Major Interests in Shares
8th May 201210:52 amRNSTR-1: Notification of Major Interest in Shares
3rd May 201212:21 pmRNSAdmission of Open Offer Shares
27th Apr 20123:37 pmRNSTR-1: Notification of Major Interest in Shares
27th Apr 20123:26 pmRNSTR-1: Notification of Major Interest in Shares
27th Apr 20127:00 amRNSResult of Placing and Open Offer
20th Apr 20122:54 pmRNSResult of General Meeting
20th Apr 20127:00 amRNSInvestor Conference
19th Apr 201210:16 amRNSNotification of Major Interest in Shares
3rd Apr 20127:00 amRNSPlacing and Open Offer
30th Mar 20127:00 amRNSIssue of Ordinary Shares
27th Mar 20127:00 amRNSExercise of Warrants
17th Jan 20127:00 amRNSWebcast and content of Stem Cell Technical Seminar
11th Jan 201212:20 pmRNSChange of Adviser and Broker
11th Jan 20127:00 amRNSStability of lead stem cell line
9th Jan 201210:00 amRNSReNeuron to present at US healthcare conference
9th Jan 20127:00 amRNSNotification of Stem Cell Technical Seminar

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.